全文获取类型
收费全文 | 8697篇 |
免费 | 994篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 288篇 |
妇产科学 | 456篇 |
基础医学 | 1019篇 |
口腔科学 | 161篇 |
临床医学 | 1526篇 |
内科学 | 1530篇 |
皮肤病学 | 130篇 |
神经病学 | 777篇 |
特种医学 | 660篇 |
外科学 | 1003篇 |
综合类 | 189篇 |
一般理论 | 5篇 |
预防医学 | 768篇 |
眼科学 | 44篇 |
药学 | 435篇 |
中国医学 | 1篇 |
肿瘤学 | 608篇 |
出版年
2021年 | 107篇 |
2020年 | 81篇 |
2019年 | 111篇 |
2018年 | 154篇 |
2017年 | 172篇 |
2016年 | 174篇 |
2015年 | 193篇 |
2014年 | 258篇 |
2013年 | 300篇 |
2012年 | 330篇 |
2011年 | 358篇 |
2010年 | 291篇 |
2009年 | 279篇 |
2008年 | 341篇 |
2007年 | 368篇 |
2006年 | 323篇 |
2005年 | 328篇 |
2004年 | 303篇 |
2003年 | 305篇 |
2002年 | 269篇 |
2001年 | 281篇 |
2000年 | 253篇 |
1999年 | 280篇 |
1998年 | 159篇 |
1997年 | 169篇 |
1996年 | 166篇 |
1995年 | 150篇 |
1994年 | 108篇 |
1993年 | 91篇 |
1992年 | 161篇 |
1991年 | 196篇 |
1990年 | 189篇 |
1989年 | 203篇 |
1988年 | 170篇 |
1987年 | 165篇 |
1986年 | 158篇 |
1985年 | 182篇 |
1984年 | 125篇 |
1983年 | 111篇 |
1982年 | 80篇 |
1981年 | 74篇 |
1980年 | 74篇 |
1979年 | 89篇 |
1978年 | 84篇 |
1977年 | 80篇 |
1976年 | 76篇 |
1975年 | 74篇 |
1974年 | 78篇 |
1973年 | 75篇 |
1972年 | 67篇 |
排序方式: 共有9705条查询结果,搜索用时 312 毫秒
1.
2.
Inna Y. Gong Nigel S. Tan Sammy H. Ali Gerald Lebovic Muhammad Mamdani Shaun G. Goodman Dennis T. Ko Andreas Laupacis Andrew T. Yan 《The Canadian journal of cardiology》2019,35(5):653-660
Background
Although it is known that women do not participate in trials as frequently as men, there are limited recent data examining how women recruitment has changed over time.Methods
We conducted MEDLINE search using a validated strategy for randomized trials published in New England Journal of Medicine, Lancet, and Journal of the American Medical Association between 1986 and 2015, and included trials evaluating pharmacologic or nonpharmacologic therapies. We abstracted data on demographics, intervention type, clinical indication, and trial design characteristics, and examined their relationships with women enrollment.Results
In total, 598 trials met inclusion criteria. Women enrollment increased significantly over time (21% between 1986 and 1990 to 33% between 2011 and 2015; Pfor trend < 0.001) and did not differ by journal or funding source. Women enrollment varied with clinical indication, comprising 37% for non–coronary artery disease vascular trials, 30% for coronary artery disease trials, 28% for heart failure trials, and 28% for arrhythmia trials (P < 0.001), which were all significantly lower than the expected proportion in disease populations (P < 0.001). Women enrollment varied with trial type (31%, 29%, and 26% for pharmacologic, device, and procedural trials, respectively; P = 0.001). These findings were corroborated using multivariable analysis. We found significant positive correlations between women enrolled, and mean age and total number of participants. Fewer women were enrolled in trials reporting statistically significant results than those who did not (P = 0.001).Conclusions
Although enrollment of women has increased over time, it remains lower than the relative proportion in the disease population. Future studies should elucidate the reasons for persistent under-representation of women in clinical trials. 相似文献3.
4.
Otavio Berwanger Renato D. Lopes Diogo D.F. Moia Francisco A. Fonseca Lixin Jiang Shaun G. Goodman Stephen J. Nicholls Alexander Parkhomenko Oleg Averkov Carlos Tajer Germán Malaga Jose F.K. Saraiva Helio P. Guimaraes Pedro G.M. de Barros e Silva Lucas P. Damiani Renato H.N. Santos Denise M. Paisani Tamiris A. Miranda Jose C. Nicolau 《Journal of the American College of Cardiology》2019,73(22):2819-2828
BackgroundThe efficacy of ticagrelor in the long-term post–ST-segment elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remains uncertain.ObjectivesThe purpose of this study was to evaluate the efficacy of ticagrelor when compared with clopidogrel in STEMI patients treated with fibrinolytic therapy.MethodsThis international, multicenter, randomized, open-label with blinded endpoint adjudication trial enrolled 3,799 patients (age <75 years) with STEMI receiving fibrinolytic therapy. Patients were randomized to ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300- to 600-mg loading dose, 75 mg daily thereafter). The key outcomes were cardiovascular mortality, myocardial infarction, or stroke, and the same composite outcome with the addition of severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events at 12 months.ResultsThe combined outcome of cardiovascular mortality, myocardial infarction, or stroke occurred in 129 of 1,913 patients (6.7%) receiving ticagrelor and in 137 of 1,886 patients (7.3%) receiving clopidogrel (hazard ratio: 0.93; 95% confidence interval: 0.73 to 1.18; p = 0.53). The composite of cardiovascular mortality, myocardial infarction, stroke, severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events occurred in 153 of 1,913 patients (8.0%) treated with ticagrelor and in 171 of 1,886 patients (9.1%) receiving clopidogrel (hazard ratio: 0.88; 95% confidence interval: 0.71 to 1.09; p = 0.25). The rates of major, fatal, and intracranial bleeding were similar between the ticagrelor and clopidogrel groups.ConclusionAmong patients age <75 years with STEMI, administration of ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of cardiovascular events when compared with clopidogrel. (Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis [TREAT]; NCT02298088) 相似文献
5.
6.
7.
8.
9.
10.